Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.10, Zacks reports. Vistagen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 48.12%.
Vistagen Therapeutics Trading Up 0.8%
Shares of Vistagen Therapeutics stock traded up $0.02 during trading on Tuesday, hitting $2.38. The stock had a trading volume of 297,351 shares, compared to its average volume of 171,739. Vistagen Therapeutics has a 12 month low of $1.90 and a 12 month high of $4.21. The firm has a market cap of $68.69 million, a price-to-earnings ratio of -1.61 and a beta of 0.70. The business's 50-day moving average is $2.30 and its 200 day moving average is $2.58.
Institutional Investors Weigh In On Vistagen Therapeutics
An institutional investor recently bought a new position in Vistagen Therapeutics stock. Cubist Systematic Strategies LLC purchased a new stake in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 10,088 shares of the company's stock, valued at approximately $25,000. Institutional investors own 78.39% of the company's stock.
Vistagen Therapeutics Company Profile
(
Get Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider VistaGen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VistaGen Therapeutics wasn't on the list.
While VistaGen Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
